

Cognitive Challenges in Treatment Trials for Epilepsy and Multiple Sclerosis

ISCTM

September 6th, 2019

Copenhagen, Denmark

Jill Rasmussen

Christoph Helmstaedter

10:30-12:00	Session 2: Cognitive challenges in treatment trials for epilepsy and multiple sclerosis	ISCTM Chair Jill Rasmussen ECNP Chair Christoph Helmstaedter
10:30	Current status of evaluation of cognition in psychiatry and neurology— issues and challenges	Jill Rasmussen
10:35	Neuropsychology in epilepsy: Assessment challenges and issues	Christoph Helmstaedter
10:50	Discussion	
11:00	Cognition in epilepsy: Issues, challenges, clinical trials to date, next steps	Kimford Meador
11:20	Discussion	
11:30	Cognition in multiple sclerosis: Measurement and application to clinical trials	Dawn Langdon
11:50	Discussion	
12:00	Regulatory perspective on cognitive challenges in treatment trials for epilepsy and multiple sclerosis	Marion Haberkamp
12:15	Panel Discussion	

Declaration of Interests

Consultancy / Advisory Boards / Speakers Bureau:

- ▶ psi-napse
- ▶ Alz Soc, Andera Partners, Biogen, ConSynance, Eli Lilly, ExCiva, Lundbeck, Merck, Nutricia, Roche, Wellcome Trust

Royal College of General Practitioners

- ▶ Clinical Representative Dementia
- ▶ Member Learning Disability Special Interest Group
- ▶ Founder of Dementia Roadmap

NHS:

- ▶ Advisor Academic Health Science Network Kent, Surrey, Sussex; Surrey Heartlands STP
- ▶ Co-developer of MoodHive (Depression Anxiety Pathway)

Current Status of Evaluation of Cognition in Psychiatry and Neurology— Issues and Challenges

Matrics Consensus Cognitive Battery MATRICS:

- ▶ Designed to stimulate the development of psychopharmacological agents to improve cognition in schizophrenia
- ▶ Intended to provide a relatively brief evaluation of key cognitive domains relevant to schizophrenia and related disorders
- ▶ Designed to address the following purposes:
 - An outcome measure for clinical trials of cognition-enhancing drugs for schizophrenia
 - An outcome measure for studies of cognitive remediation
 - A measure of cognitive change in repeated testing applications
 - A cognitive reference point for non-intervention studies of schizophrenia and related disorders:

Current Status of Evaluation of Cognition in Psychiatry and Neurology— Issues and Challenges

MCCB Tests included involved a broad-based interdisciplinary consensus process :

1. Speed of processing
2. Attention/vigilance
3. Working memory
4. Verbal learning
5. Visual learning
6. Reasoning and problem solving
7. Social cognition

BUT

Cognitive dysfunction an issue in many CNS disorders

Depression:

- Significant problems with attention, executive functioning, immediate recall and processing speed, despite achieving remission resulting in functional impairment

Epilepsy

- Impact of underlying cause of epilepsy, seizures, AEDs

Multiple Sclerosis

- Relationship with disability

Cognitive Dysfunction in Epilepsy and Multiple Sclerosis

Cognitive Domains affected maybe similar between these conditions and with other CNS disorders

BUT

How Cognitive Dysfunction in these disorders is assessed and addressed:

- Requires deeper consideration
- Has important implications for clinical trial design

10:30-12:00	Session 2: Cognitive challenges in treatment trials for epilepsy and multiple sclerosis	ISCTM Chair Jill Rasmussen ECNP Chair Christoph Helmstaedter
10:30	Current status of evaluation of cognition in psychiatry and neurology— issues and challenges	Jill Rasmussen
10:35	Neuropsychology in epilepsy: Assessment challenges and issues	Christoph Helmstaedter
10:50	Discussion	
11:00	Cognition in epilepsy: Issues, challenges, clinical trials to date, next steps	Kimford Meador
11:20	Discussion	
11:30	Cognition in multiple sclerosis: Measurement and application to clinical trials	Dawn Langdon
11:50	Discussion	
12:00	Regulatory perspective on cognitive challenges in treatment trials for epilepsy and multiple sclerosis	Marion Haberkamp
12:15	Panel Discussion	